InterAction Database (IADB)


Description

The InterAction Database includes demographic and prescription information for more than 500,000 patients in the northern and middle Netherlands and has been integrated with other systems to enhance data collection and analysis. No specific mention was made of the inclusion of information on cancer-related outcomes.

Selected References

Utilization

Faber A, Bouvy ML, Loskamp L, van de Berg PB, Egberts TC, de Jong-van den Berg LT. Dramatic change in prescribing of hormone replacement therapy in The Netherlands after publication of the Million Women Study: a follow-up studyExternal Web Site Policy. Br J Clin Pharmacol. 2005 Dec;60(6):641-7.

Cost/Cost Effectiveness

Jansman FG, Postma MJ, van Hartskamp D, Willemse PH, Brouwers JR. Cost-benefit analysis of capecitabine versus 5-fluorouracil/leucovorin in the treatment of colorectal cancer in the NetherlandsExternal Web Site Policy. Clin Ther. 2004 Apr;26(4):579-89.

Treatment/Survivorship

Kho Y, Jansman FG, Prins NH, Neef C, Brouwers JR. Population pharmacokinetics of oxaliplatin (85 mg/m2) in combination with 5-fluorouracil in patients with advanced colorectal cancerExternal Web Site Policy. Ther Drug Monit. 2006 Apr;28(2):206-11.

Jansman FG, Idzinga FS, Smit WM, de Graaf JC, Coenen JL, Sleijfer DT, Brouwers JR. Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancerExternal Web Site Policy. Clin Ther. 2005 Mar;27(3):327-35.

Jansman FG, Jansen AJ, Coenen JL, de Graaf JC, Smit WM, Sleijfer DT, Brouwers JR. Assessing the clinical significance of drug interactions with fluorouracil in patients with colorectal cancerExternal Web Site Policy. Am J Health Syst Pharm. 2005 Sep 1;62(17):1788-93.

Return to Top